Discover
PMCB
PharmaCyte Biotech, Inc.
0.74
2 x 0.54
2 x 0.98
bid
ask
-
0.03
3.77%
2 @ 04:00 PM
0.74 -0.00 (0.13%)
| Ytd | 2.35% | |
| 1y | -35.00% |
0.74
day range
0.79
0.63
52 week range
1.51
| Open | 0.79 | Prev Close | 0.77 | Low | 0.74 | High | 0.79 | Mkt Cap | 7.96M |
| Vol | 60.09K | Avg Vol | 180.65K | EPS | -0.89 | P/E | N/A | Forward P/E | -4.21 |
| Beta | -0.20 | Short Ratio | 1.09 | Inst. Own | 13.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.77 | 200-d Avg | 0.82 | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-13 | 2024-10 | 0 | -0.29 | N/A | N/A |
| 2024-09-16 | 2024-07 | 0 | 0.14 | N/A | N/A |
| 2024-08-13 | 2024-04 | 0 | -0.85 | N/A | N/A |
| 2024-03-18 | 2024-01 | 0 | -0.65 | N/A | N/A |
| 2023-12-15 | 2023-10 | 0 | -0.64 | N/A | N/A |
| 2023-09-18 | 2023-07 | 0 | -0.28 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2021-11-08 | HC Wainwright & Co. | Upgrade | Neutral |
Profile
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Geode Capital Management, LLC | 168.20K | 269.12K | 0.01% |
| 2024-09-29 | Vanguard Group Inc | 192.39K | 307.82K | 0.01% |
| 2024-09-29 | K2 Principal Fund, L.P. | 209.27K | 334.83K | 0.01% |
| 2024-09-29 | Equitec Proprietary Markets LLC | 82.73K | 132.36K | 0.00% |
| 2024-09-29 | Dimensional Fund Advisors LP | 27.60K | 44.16K | 0.00% |
| 2024-09-29 | Renaissance Technologies, LLC | 49.70K | 79.52K | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Schwab Capital Trust-Total Stock Market Index Fund | 5.95K | 9.52K | 0.00% |
| 2024-07-30 | DFA U.S. Targeted Value Portfolio | 2.01K | 3.21K | 0.00% |
| 2024-07-30 | Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | 11.51K | 18.41K | 0.00% |
| 2024-07-30 | Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 8.71K | 13.93K | 0.00% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 117.47K | 187.95K | 0.00% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 74.92K | 119.87K | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 1492 | 2021-07-12 |